Β-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia.

Qin Chen,Val J. Lowe,Bradley F. Boeve,Scott A. Przybelski,Toji Miyagawa,Matthew L. Senjem,Clifford R. Jack,Timothy G. Lesnick,Walter K. Kremers,Julie A. Fields,Hoon-Ki Min,Christopher G. Schwarz,Jeffrey L. Gunter,Jonathan Graff-Radford,Rodolfo Savica,David S. Knopman,David Jones,Tanis J. Ferman,Neill R. Graff-Radford,Ronald C. Petersen,Kejal Kantarci

DOI: https://doi.org/10.1212/wnl.0000000000011454

IF: 9.9

2021-01-01

Neurology

Abstract:Objective To determine the clinical phenotypes associated with the beta-amyloid PET and dopamine transporter imaging (I-123-FP-CIT SPECT) findings in mild cognitive impairment (MCI) with the core clinical features of dementia with Lewy bodies (DLB; MCI-LB). Methods Patients with MCI who had at least 1 core clinical feature of DLB (n = 34) were grouped into beta-amyloid A(+) or A-and I-123-FP-CIT SPECT D+ or D- groups based on previously established abnormality cut points for A+ with Pittsburgh compound B PET standardized uptake value ratio (PiB SUVR) >= 1.48 and D+ with putamen z score with DaTQUANT <-0.82 on I-123-FPCIT SPECT. Individual patients with MCI-LB fell into 1 of 4 groups: A+D+, A+D-, A-D+, or A-D-. Log-transformed PiB SUVR and putamen z score were tested for associations with patient characteristics. Results The A-D+ biomarker profile was most common (38.2%), followed by A+D+ (26.5%) and A-D- (26.5%). The least common was the A+D- biomarker profile (8.8%). The A+ group was older, had a higher frequency of APOE epsilon 4 carriers, and had a lower Mini-Mental State Examination score than the A- group. The D+ group was more likely to have probable REM sleep behavior disorder. Lower putamen DaTQUANT z scores and lower PiB SUVRs were independently associated with higher Unified Parkinson's Disease Rating Scale-III scores. Conclusions A majority of patients with MCI-LB are characterized by low beta-amyloid deposition and reduced dopaminergic activity. beta-Amyloid PET and 123I-FP-CIT SPECT are complementary in characterizing clinical phenotypes of patients with MCI-LB.